Concepedia

Selena Rush

SR

11

Publications

385

Citations

10

H-Index

2011

Active since

Affiliations

Array BioPharma (United States)(Current)

Emory University

The Barbara Ann Karmanos Cancer Institute

Wayne State University

The University of Texas MD Anderson Cancer Center

Selena Rush is an author at Array BioPharma (United States) specializing in oncology, medicine, and radiation oncology.

Top concepts

Publications per year

2011–2021

11

Publications

11

A Phase 1 and 2 study of Filanesib alone and in combination with low‐dose dexamethasone in relapsed/refractory multiple myeloma

Jatin J. Shah, Jonathan L. Kaufman, Jeffrey A. Zonder et al. · Cancer · 2017 · 72 citations · Full text

A phase 1 dose‐escalation study of ARRY‐520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias

H. Jean Khoury, Guillermo Garcia‐Manero, Gautam Borthakur et al. · Cancer · 2011 · 64 citations · Full text

A Phase I Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes

Guillermo Garcia‐Manero, H. Jean Khoury, Elias Jabbour et al. · Clinical Cancer Research · 2014 · 54 citations · Full text

First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors

Patricia LoRusso, Priscila Gonçalves, Lindsay Casetta et al. · Investigational New Drugs · 2015 · 46 citations

, , +8

A phase 1 dose‐escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma

Ajai Chari, Myo Htut, Jeffrey A. Zonder et al. · Cancer · 2016 · 36 citations

Rows per page

1–5 of 11